Dabur India Clarifies US FDA Warning Letter for Silvassa Plant

NEW DELHI — Dabur India Limited has received a formal warning letter from the United States Food & Drug Administration (US FDA) regarding its manufacturing unit located in Silvassa, Dadra and Nagar Haveli. The company disclosed the development in a regulatory filing submitted to stock exchanges on August 6, 2026, clarifying that the action is strictly limited to export products and carries no material impact on its domestic operations or overall financial performance.

The warning letter summarizes previous audit findings by the US health regulator concerning data integrity and facility maintenance lapses at the Silvassa site. While the US FDA has requested additional details on Dabur's corrective and preventive action plan, the company confirmed that domestic production remains fully operational and entirely unaffected by the order.

Background and Remediation Progress

The warning letter represents a continuation of post-audit regulatory procedures by the US FDA following earlier observations. On June 10, 2026, the US FDA had issued Import Alert 66-40 for drug products manufactured at the Silvassa facility.

In response, Dabur India has taken extensive remediation steps, completing four progress updates in coordination with the regulator. Key mitigating actions already undertaken by the company include:

• Data Integrity Training: Rollout of specialized training programs across all manufacturing operations.

• Independent Oversight: Appointment of an additional, independent compliance resource tasked with continuous oversight and monitoring of data integrity controls.

• Infrastructure Upgrades: Completion of all observed infrastructure-related remediation tasks within 30 days.

• Risk Assessment: Execution of a comprehensive retrospective risk assessment across affected processes, systems, and product lines.

• External Advisory: Engagement of a U.S.-based compliance consulting firm to assist in the verification and long-term implementation of corrective measures.

Operational Scope and Financial Impact

Dabur India assured investors and consumers that the US FDA warning letter concerns only a minor section of the Silvassa plant dedicated to private label exports, which contributes an insignificant share of overall company revenue.

Independent testing conducted internally and by third parties confirmed no out-of-specification results or quality issues across Dabur's product catalog. To ensure seamless delivery for international clients, Dabur has enacted alternate sourcing strategies to supply its U.S. customer base while remediation continues.

Official Sources Section

Information regarding the regulatory update was communicated by Group Company Secretary and Chief Compliance Officer Ashok Kumar Jain via an official disclosure filed under Regulation 30 of the SEBI Listing Obligations & Disclosure Requirements Regulations, 2015. The submission was delivered to the BSE Limited and the National Stock Exchange of India Limited on August 6, 2026. Corporate governance filings are maintained under standards oversaw by the Ministry of Finance and market regulators.

Quote Section

According to company officials, "The warning notice concerns only a small part of our manufacturing plant situated at Silvassa, Dadra and Nagar Haveli, in relation to export of private label products, which does not generate significant revenue for the Company. Domestic products are not covered and not impacted by this order."

Why It Matters

The clarification provides essential transparency for investors and consumers evaluating Dabur India's market stance. By confirming that domestic operations are completely isolated from the US FDA notice, Dabur mitigates supply chain concerns for Indian consumers while preserving core revenue drivers. Furthermore, proactive remediation efforts demonstrate corporate commitment to international compliance standards without disrupting domestic availability.

Key Facts at a Glance

• Authority Action: US FDA issued a warning letter summarizing post-inspection findings at Dabur's Silvassa plant.

• Affected Segment: Private label export products only; domestic products are not covered.

• Operational Status: Silvassa plant remains fully operational for all domestic product lines.

• Response Timeline: Formal response to the US FDA will be submitted within 15 working days.

• Financial Impact: Zero quantifiable impact on financial or overall operational activities.

FAQ Section

Why did Dabur India receive a warning letter from the US FDA?

The US FDA issued the warning letter as part of post-audit procedures following an inspection at the Silvassa facility, requesting additional details on Dabur's corrective and preventive action plan regarding data integrity and maintenance.

Are domestic Dabur products safe and available?

Yes. The regulatory notice applies exclusively to private label export items produced at a specific portion of the Silvassa facility. Domestic manufacturing, quality testing, and supply chains are completely unaffected.

What steps is Dabur taking to resolve the US FDA concerns?

Dabur has completed infrastructure fixes, implemented data integrity training, appointed an independent oversight team, conducted process risk assessments, and engaged a US-based compliance consulting firm.

Source: Dabur India Limited Corporate Filings submitted to BSE Limited and National Stock Exchange of India Limited. Corporate compliance monitored by the Ministry of Finance.